Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most
common type being venous thromboembolism (VTE). Several risk factors for develo** …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

Background: The risk of arterial thromboembolism in patients with cancer is incompletely
understood. Objectives: The authors aimed to better define this epidemiological relationship …

Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Background This guideline addressed VTE prevention in hospitalized medical patients,
outpatients with cancer, the chronically immobilized, long-distance travelers, and those with …

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity
and mortality. VTE prevention and treatment are more complex in patients with cancer. The …

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …

BACKGROUND: Accurate population-based data are needed on the incidence of venous
thromboembolism (VTE) in patients with different cancers in order to inform guidelines on …

Malignancy affects the hemostatic system and the hemostatic system affects malignancy. In
cancer patients there are a number of coagulation abnormalities which provide the …